A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease
Latest Information Update: 18 Apr 2025
At a glance
- Drugs REM 0046127 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors reMYND
Most Recent Events
- 03 Apr 2025 According to a a reMYND Media Release, the company has recently collaborated with Unlearn- a leader in AI solutions for clinical trials, to focus on on remynd's Phase 2a clinical trial of REM127. Unlearn supported the study by applying its Alzheimer's Disease-specific Digital Twin Generator (AD DTG). These digital twins served as individualized comparators, providing additional evidence for interpreting and extrapolating the changes observed in the treated population.
- 04 Jun 2024 Status changed from recruiting to discontinued. (Reason the study was stopped: Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.)
- 26 Apr 2024 This trial has been discontinued in Spain.